Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

February 24, 2020

Trulicity gets FDA nod for reducing CV risk in type 2 diabetes patients

Eli Lilly and Company (Lilly) has been granted approval for Trulicity (dulaglutide) from the US Food and Drug Administration (FDA) for reducing the risk of major adverse cardiovascular events (MACE) in adults having type 2 diabetes.

Trulicity gets FDA nod for reducing CV risk in type 2 diabetes patients